Treatment of acute pancreatitis with protease inhibitors administered through intravenous infusion: An updated systematic review and meta-analysis

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Seta, Takeshi ^a,d   Noguchi, Yoshinori ^b   Shikata, Satoru ^c   Nakayama, Takeo ^d  

^a JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

^b NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^c Mie Prefectural Ichishi Hospital   (Japan)

^d KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

Author keywords

Acute pancreatitis; Complication; Control mortality rate; Mortality; Protease inhibitors

Indexed keywords

APROTININ; GABEXATE MESILATE; PROTEINASE INHIBITOR; GABEXATE; SERINE PROTEINASE INHIBITOR;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ACUTE PANCREATITIS; ARTICLE; ATTRIBUTABLE RISK; CAUSE OF DEATH; CONTROL MORTALITY RATE; DRUG EFFICACY; GASTROINTESTINAL HEMORRHAGE; GENETIC HETEROGENEITY; HUMAN; HYPOXIA; INTESTINE OBSTRUCTION; KIDNEY FAILURE; META ANALYSIS; METABOLIC DISORDER; MORTALITY; NUMBERS NEEDED TO TREAT; PSEUDOCYST; PUBLISHING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; RISK REDUCTION; SENSITIVITY ANALYSIS; SEPSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ACUTE DISEASE; INTRAVENOUS DRUG ADMINISTRATION; PANCREATITIS; SEVERITY OF ILLNESS INDEX;

ACUTE DISEASE; APROTININ; GABEXATE; HUMANS; INFUSIONS, INTRAVENOUS; PANCREATITIS; PROTEASE INHIBITORS; SERINE PROTEINASE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84902547083     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-102     Document Type: Article

References (58)

1. Cavallini G, Frulloni L, Bassi C, Gabbrielli A, Castoldi L, Costamagna G, De Rai P, Di Carlo V, Falconi M, Pezzilli R, Uomo G, . ProInf-AISP Study Group Prospective multicentre survey on acute pancreatitis in Italy (ProInf-AISP): results on 1005 patients. Dig Liver Dis 2004, 36:205-211. 10.1016/j.dld.2003.11.027, 15046191, ProInf-AISP Study Group.
2. Banks PA, Freeman ML. Practice parameters Committee of the American college of gastroenterology. practice guidelines in acute pancreatitis. Am J Gastroenterol 2006, 101:2379-2400. 10.1111/j.1572-0241.2006.00856.x, 17032204.
3. Al-Omran M, Albalawi ZH, Tashkandi MF, Al-Ansary LA. Enteral versus parenteral nutrition for acute pancreatitis. Cochrane Database Syst Rev 2010, 20:CD002837.
4. Brownfield E. Pain management. Making Healthcare Safer: A Critical Analysis of Patient Safety Practices. AHRQ Evidence Report/Technology Assessment Number 43 http://www.ahrq.gov/clinic/ptsafety/pdf/chap37.pdf.
5. Morimoto T, Noguchi Y, Sakai T, Shimbo T, Fukui T. Acute pancreatitis and the role of histamine-2 receptor antagonists: a meta-analysis of randomized controlled trials of cimetidine. Eur J Gastroenterol Hepatol 2002, 14:679-686. 10.1097/00042737-200206000-00014, 12072603.
6. Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg 1996, 17:394-398.
7. Takeda K, Yamauchi J, Shibuya K, Sunamura M, Mikami Y, Matsuno S. Benefit of continuous regional arterial infusion of protease inhibitor and antibiotic in the management of acute necrotizing pancreatitis. Pancreatol 2001, 1:668-673.
8. Imaizumi H, Kida M, Nishimaki H, Okuno J, Kataoka Y, Kida Y, Soma K, Saigenji K. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas 2004, 28:369-373. 10.1097/00006676-200405000-00003, 15097852.
9. Piaścik M, Rydzewska G, Milewski J, Olszewski S, Furmanek M, Walecki J, Gabryelewicz A. The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study. Pancreas 2010, 39:863-867. 10.1097/MPA.0b013e3181d37239, 20431422.
10. Seta T, Noguchi Y, Shimada T, Shikata S, Fukui T. Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. Eur J Gastroenterol Hepatol 2004, 16:1287-1293. 10.1097/00042737-200412000-00009, 15618834.
11. Moher D, Liberati A, Tetzlaff J, Altman DG, . PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. 10.7326/0003-4819-151-4-200908180-00135, 19622511, PRISMA Group.
12. ClinicalTrials.gov available from http://clinicaltrials.gov, ClinicalTrials.gov.
13. Controlled-trials.com available from http://www.controlled-trials.com, Controlled-trials.com.
14. UMIN Japan: University Hospital Medical Information Network, available from http://www.umin.ac.jp/ctr/index-j.htm, UMIN.
15. JMACCT Japan Medical Association Clinical Trial Registry, available from https://dbcentre3.jmacct.med.or.jp/jmactr/App/JMACTRS01/JMACTRS01.aspx?kbn=4, JMACCT.
16. JAPIC Japan Pharmaceutical Information Center. available from http://clinicaltrials.jp/user/cte_main.jsp, JAPIC.
17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12. 10.1016/0197-2456(95)00134-4, 8721797.
18. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y, Norris SL, Williams JW, Atkins D, Meerpohl J, Schünemann HJ. GRADE guidelines: 4. Tating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol 2011, 64:407-415. 10.1016/j.jclinepi.2010.07.017, 21247734.
19. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985, 41:55-68. 10.2307/2530643, 4005387.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring incomsistency in meta-analysis. BMJ 2003, 327:557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
21. DerSimonian R, Laird N. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
22. Light RJ, Pilemer DB. Summing up: the science of reviewing research. 1984, Cambridge, MA: Harvard University Press.
23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101. 10.2307/2533446, 7786990.
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 10.1136/bmj.315.7109.629, 2127453, 9310563.
25. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998, 317:1309-1312. 10.1136/bmj.317.7168.1309, 1114210, 9804726.
26. Stata/SE 11 for Windows. 2009, College Station, Texas: Stata Corporation.
27. Skyring A, Singer A, Tornya P. Treatment of acute asylol: report of a controlled therapeutic trial. BMJ 1965, 2:627-629. 10.1136/bmj.2.5462.627, 1846024, 14331623.
28. Ryall RJ. Discussion on acute pancreatitis with a report on a clinical trial of trasylol. Anglo Ger Med Rev 1966, 3:274-283.
29. Trapnell JE, Talbot CH, Capper WM. Trasylol in acute pancreatitis. Am J Dig Dis 1967, 12:409-412. 10.1007/BF02241945, 5336018.
30. Baden H, Jordal K, Lund F, Zachariae F. A double-blind controlled clinical trial of Trasylol. Preliminary results in acute pancreatitis and in prophylaxis against postoperative pancreatitis. Acta Chir Scand Suppl 1967, 378:97-102.
31. Bachrach WH, Schild PD. A double-blind study of Trasylol in the treatment of pancreatitis. Ann N Y Acad Sci 1968, 146:580-592. 10.1111/j.1749-6632.1968.tb20316.x, 4891419.
32. Möller C, Stjernvall L. Clinical trial with Trasylol against acute pancreatitis. Ann Chir Gynaecol Fenn 1969, 58:296-299.
33. Baden H, Jordal K, Lund F, Zachariae F. Prophylactic and curative action of Trasylol in pancreatitis. A double-blind trial. Scand J Gastroenterol 1969, 4:291-295.
34. Trapnell JE, Rigby CC, Talbot CH, Duncan EH. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg 1974, 61:177-182. 10.1002/bjs.1800610303, 4595174.
35. Death from acute pancreatitis. M.R.C. multicentre trial of glucagon and aprotinin. Lancet 1977, 2:632-635.
36. Gauthier A, Gillet M, Di Costanzo J, Camelot G, Maurin P, Sarles H. Controlled therapeutic trial of aprotinin and glucagon in acute pancreatitis. Gastroenterol Clin Biol 1978, 2:777-784.
37. Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O'Neill J, Blumgart LH. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 1978, 65:337-341. 10.1002/bjs.1800650514, 348250.
38. Imrie CW. Medical treatment of acute pancreatitis. Gastroenterology 1978, 75:766-767.
39. Kirsch A, Werner U, Heinze D. Proteinase inhibiting agents and glucagon in acute pancreatitis. Zentralbl Chir 1978, 103:291-303.
40. Soergel KH. Medical treatment of acute pancreatitis: what is the evidence?. Gastroenterology 1978, 74:620-628.
41. Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. Gut 1980, 21:334-339. 1419604, 6159256.
42. Freise J, Melzer P, Schmidt FW, Horbach L. Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients. Z Gastroenterol 1986, 24:200-211.
43. Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas 1987, 2:698-700. 10.1097/00006676-198711000-00013, 3125546.
44. Goebell H. Multicenter double-blind study of gabexate mesilate (Foy) given intravenously in low dose in acute pancreatitis [Abstract]. Digestion 1988, 40:83.
45. Harada H, Miyake H, Ochi K, Tanaka J, Kimura I. Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol 1991, 9:75-79.
46. Valderrama R, Pérez-Mateo M, Navarro S, Vázquez N, Sanjosé L, Adrián MJ, Estruch J. Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion 1992, 51:65-70. 10.1159/000200877, 1499875.
47. Büchler M, Malfertheiner P, Uhl W, Schölmerich J, Stöckmann F, Adler G, Gaus W, Rolle K, Beger HG. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology 1993, 104:1165-1170.
48. Cicardi M, Testoni P, Bergamaschini L, Guzzoni S, Cugno M, Buizza M, Bagnolo F. Antiproteasic activity of C1 inhibitor. Therapeutic perspectives. Ann Ital Med Int 1994, 9:180-182.
49. Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology 2000, 47:1147-1150.
50. Pezzilli R, Miglioli M. Multicentre comparative study of two schedules of gabexate mesilate in the treatment of acute pancreatitis. Italian Acute Pancreatitis Study Group. Dig Liver Dis 2001, 33:49-57. 10.1016/S1590-8658(01)80135-3, 11303975.
51. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting randomized controlled trials. The CONSORT statement. JAMA 1996, 276:637-639. 10.1001/jama.1996.03540080059030, 8773637.
52. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury I. Does the CONSORT checklist improve the quality of reports of randomized controlled trials? A systematic review. Med J Aust 2006, 185:263-267.
53. Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomized trials in 2000 and 2006: a comparative study of articles indexed by PubMed. BMJ 2010, 340:c723. 10.1136/bmj.c723, 2844941, 20332510.
54. Uetani K, Nakayama T, Ikai H, Yonemoto N, Moher D. Quality of reports on randomized controlled trials conducted in Japan: evaluation of adherence to the CONSORT statement. Inter Med 2009, 48:307-313.
55. Shikata S, Nakayama T, Yamagishi H. Quality of surgical randomized controlled trials for acute cholecystitis: assessment based on CONSORT and additional check items. J Hepatobiliary Pancreat Surg 2008, 15:297-303. 10.1007/s00534-007-1268-8, 18535768.
56. Bradley EL. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg 1993, 128:586-590. 10.1001/archsurg.1993.01420170122019, 8489394.
57. Ranson JH, Rifkind KM, Roses DF, Fink SD, Eng K, Spencer FC. Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet 1974, 139:69-81.
58. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.